In the paediatric population, there is some evidence of possible interaction, synergism, and co-toxicity of aspirin and acetaminophen. The toxicity of salicylates such as aspirin in this population is well known and documented, specifically in the form of Reye syndrome. The possible toxic synergism with aspirin and acetaminophen, however, is not previously described; though case reports suggest such co-toxicities with low levels of aspirin and other compounds can exist. In vitro studies into mechanistic processes of salicylate toxicity propose that there is a bi-directional link and potentiation with glutathione (GSH) depletion and salicylate toxicity. Data may suggest a plausible explanation for salicylate and acetaminophen toxic synergism. Further studies investigating this potential toxic synergism are warranted. Given the lack of awareness in the clinical community about potential toxic synergism between these relatively common medications, caution is advised in the co-administration of these drugs, particularly in communities using natural or alternative therapy.
| INTRODUCTION
Reye syndrome was a phenomenon first described by Dr. R.D. Reye and colleagues in 1963. 1, 2 At that time, Reye syndrome was identified as a phenomenon in children suffering from acute hepatic steatosis and fatty degeneration of the viscera along with cerebral oedema and encephalopathy. Shortly afterward, in 1965, the first association between Reye syndrome and salicylates, such as aspirin, was described in the UK. 3 This led to extensive case studies in the UK and the US from the 1970s to 1990s that identified a strong correlation between Reye syndrome and aspirin use. 1, 4 Although no causality between salicylates and Reye syndrome has been demonstrated, the burden of data from case-control studies in the UK and US has left little doubt in most physicians as to the link and the danger. 5 The incidence dropped precipitously after the US and UK health agencies came out with warnings against using aspirin in children in 1980 and 1986, respectively. 4, 6 Due to these warnings, aspirin has fallen out of favour in Western society for symptomatic management of viral illnesses in children.
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After public health campaigns against the use of aspirin for symptom management of viral upper respiratory tract infections, acetaminophen became the mainstay of treatment for these children. However, salicylates are still found in many natural remedies, such as willow-tree bark herbal tea, and with the growing popularity of natural products for the treatment of illness, this potentially allows co-ingestion of salicylate and acetaminophen. 8, 9 Previous systematic reviews investigating many botanical agents have demonstrated the potential hepatoxicity of these agents, including some case reports with salicylates and herbal teas at seemingly benign doses. 9 The possible toxic synergism of acetaminophen and aspirin has not been previously clarified. It is our aim to review Reye syndrome and
Reye-like syndrome in the current literature and to explore if it is relatable to possible toxic synergism with co-ingestion of salicylates with other drugs such as acetaminophen.
Relevant scientific articles published between 1900 through to 2017 from four databases including PubMed, Cochrane Database of Systematic Reviews, Embase, and Google Scholar were reviewed using a systematic search. Search terms were as follows: Reye syndrome, aspirin toxicity, salicylate toxicity, acetaminophen toxicity, paracetamol toxicity, acetaminophen and salicylate toxicity, acetaminophen and salicylate interactions, glutathione related toxicity, histopathology of Reye syndrome, and treatment of Reye syndrome. The search was restricted to English language articles, and only articles that were systematic reviews, case-controlled studies, retrospective studies, case reports, in vitro studies and in vivo studies were included.
Due to the heterogeneity of the papers and the lack of quantitative data in the literature on this topic, a quantitative analysis of literature data was not possible, and we were restricted to the qualitative analysis of the available studies.
| RESULTS
Our research generated 897 relevant articles, of which 871 (746 + 125)
were excluded based on the criteria mentioned above of language and type of articles, respectively. Figure 1 shows the selection process.
This search identified several case-control and retrospective studies relevant to the evolution of scientific data of Reye syndrome in the paediatric population. There is a moderate number of articles discussing anatomy and histopathology of Reye syndrome. Several articles also discussed acetaminophen toxicity both clinically and histologically. However, there is a limited number of scientific articles exploring the aetiology of Reye syndrome and interactions and co-toxicity of acetaminophen and salicylate. Articles exploring mechanism of interactions between the two compounds were extremely limited, and there is only one in vitro study directly exploring the interaction between acetaminophen and salicylates.
| Clinical presentation of Reye and Reye-like syndrome
Reye syndrome is a biphasic illness. The first phase is characterized by a viral prodrome lasting several days and is followed by 1-5 days of remission. The second phase involves acute onset of several symptoms leading to the medical presentation. These symptoms follow a predictable pattern: profuse and effortless vomiting, followed by a rapidly evolving neurological decline with irritability and possible convulsions, and later decreased neurological status, generally seen with a decrease in Glasgow Coma Scale scores, and sometimes death in up to 40% of cases. 1, 10 This process can be associated with an unexplained non-inflammatory encephalopathy and raised intracranial pressure, elevation of aspartate transaminase, alanine transaminase, ammonia levels, and hepatic fatty infiltration with pan-lobular microvesicular change on liver histology. 
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Regarding natural substances, there has been much less literature documenting potential associations with Reye syndrome. Suggested natural substances that may have an association with Reye syndrome include hypoglycin, pentanoate, and plant toxins. [11] [12] [13] There are many natural products that are known to cause hepatic failure, which may 
| Aetiology
Reye syndrome is perhaps most controversial when discussing the aetiology. Some experts attribute the high incidence rate in the early history of the disease, as well as a precipitous decline in the 1980s, to misdiagnosis of inherited metabolic disorders in the early cases.
Common metabolic disorders that clinically could be confused with true Reye syndrome include single enzyme defects of primary carnitine deficiency, hereditary fructose intolerance, methylmalonic acidemia, and 3-hydroxy-3-methyl-glutarate lyase deficiency. 1,10 These inherited metabolic disorders can be diagnosed today on frozen liver tissue samples, but many of the autopsies done in the past failed to collect these tissue samples.
The typical description of true Reye syndrome includes a viral prodrome that precedes a precipitous fulminant hepatic failure. The exact mechanism of this relationship is not well understood. The most prevalent proposed mechanism involves the release of cytokines during a viral illness that may predispose a child to develop Reye syndrome.
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Viral RNA diverts host endoplasmic reticulum to synthesize viral protein, which is known to disrupt the Kupffer cells in the liver. This setting releases endotoxins such as tumor necrosis factor alpha (TNFɑ) and interleukin 1 (IL-1), which has been documented in the plasma and central spinal fluid (CSF) of patients with Reye syndrome. 16 In animal models, the release of cytokines, such as TNFɑ, from macrophages is known to have a wide range of effects including inhibition of β-oxidation of long chain fatty acids in hepatocytes. 17, 18 This aspect leads to increased levels of plasma ammonia and free fatty acids, which causes mitochondrial damage and hepatic fatty infiltration.
| Salicylate metabolism
The link between ASA and Reye syndrome has been established with a large body of correlative evidence in the past. The exact mechanism, however, remains a mystery. Furthermore, Reye syndrome can also be observed with a variety of other medications and has even been described in the absence of additional factors other than a viral prodrome. 1 ASA's mechanism of action for its therapeutic effects are well known at this point: it irreversibly binds and inactivates the cyclooxygenase (COX) enzyme, resulting in decreased levels of prostaglandins and thromboxane that are responsible for a myriad of effects, including ASA's anti-inflammatory properties. 
| GSH metabolism and interactions
Acetaminophen toxicity is attributed to the depletion of glutathione (GSH), which is covalently bound by a metabolite of acetaminophen.
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GSH is critical to preserving redox homeostasis and mitochondrial function. GSH depletion due to acetaminophen toxicity would result in increased oxidative stress and creation of proinflammatory cytokines, leading to hepatitis. 21 Given that ASA induces anti-inflammatory effects, it was thought originally that there was no synergistic effect in hepatic toxicity by co-ingestion of the two compounds.
However, this was not reflected in in vitro experiments with GSH depletion and ASA exposure. 22 Raza and John simulated GSH depletion using buthionine (BSO), which inhibits the rate limiting step of GSH synthesis. 
| DISCUSSION
The use of analgesics and antipyretics for the management of illnesses such as viral infections are of routine practice. Previously, when the popularity of salicylates was at its peak, a phenomenon known as Reye syndrome occurred at a fairly high incidence rate and involved cerebral edema, neurologic compromise, acute hepatitis, and possibly hepatic failure-especially in the paediatric population. 1, [4] [5] [6] [7] 10 Through the large burden of data collected through surveillance in the US and UK, one assumes there may be a causal link between developing Reye syndrome and ingesting salicylates in the setting of a viral prodrome.
1, [4] [5] [6] 10, 11 This situation has prompted warnings against using salicylates for children with infectious symptoms since the 1980s. 1, [4] [5] [6] [7] 10 The public well heeded these warnings, and in place of salicylates, acetaminophen was used for symptomatic control of paediatric viral illnesses.
Continued surveillance data into the 1990s has shown a marked drop of Reye syndrome and associated fatalities. Contemporary rates have dropped to around 0.79 in 1 000 000 children. respectively. Therefore, we consider that further research in this field is necessary. Caution in the current use of acetaminophen and ASA should be exercised until further studies are done. 
| CONCLUSION

